Unit dose bulk material sampling apparatus
    7.
    发明授权
    Unit dose bulk material sampling apparatus 失效
    单位剂量散装材料采样仪

    公开(公告)号:US5476017A

    公开(公告)日:1995-12-19

    申请号:US136139

    申请日:1993-10-15

    CPC分类号: G01N1/08 G01N2001/1006

    摘要: Apparatus for removing a sample of granular or powder materials from a vat in which such materials are mixed in bulk, including an elongated probe having a sample receiving cavity at one end which may be adjusted to a predetermined volume. The probe is inserted in the bulk mixture to a predetermined depth, the cavity loaded with material from the bulk and after closing the cavity, the probe is removed from the bulk removing therefrom a sample of a desired predetermined quantity representative of the bulk mixture at the insertion point. A backing plate is also provided in the probe to compact the sample in the cavity to facilitate handling of the sample.

    摘要翻译: 用于从其中大量混合这种材料的槽中除去颗粒或粉末材料样品的装置,包括在一端具有可以调节到预定体积的样品接收腔的细长探针。 将探针插入大体积混合物中至预定的深度,空腔中装有来自本体的材料,并且在封闭空腔之后,将探针从体内移除,从而将探针从其中去除,代表在 插入点 还在探针中提供背板以压缩空腔中的样品以便于处理样品。

    Medicaments with hm74a receptor activity
    10.
    发明申请
    Medicaments with hm74a receptor activity 有权
    具有hm74a受体活性的药物

    公开(公告)号:US20070135456A1

    公开(公告)日:2007-06-14

    申请号:US10589474

    申请日:2005-02-10

    IPC分类号: A61K31/522 C07D473/02

    CPC分类号: C07D473/06 C07D473/04

    摘要: The present invention provides therapeutically active compounds which are xanthine derivatives, processes for the manufacture of said derivatives, pharmaceutical formulations containing the active compounds and the use of the compounds in therapy, particularly in the treatment of diseases where under-activation of the HM74A receptor contributes to the disease or where activation of the receptor will be beneficial, having the formula (II): wherein R1 is selected from: hydrogen and C1-4 alkyl which may be optionally substituted with one or more groups selected from CN and CF3, R2 is selected from: C2-10 unsubstituted alkyl, C1-10 alkyl substituted with one or more groups selected from fluorine and CN, C5 alkenyl, unbranched C4 alkenyl, and C1-4 alkyl substituted with cycloalkyl, and R3 is selected from halogen and CN.

    摘要翻译: 本发明提供治疗活性化合物,其为黄嘌呤衍生物,制备所述衍生物的方法,含有活性化合物的药物制剂以及该化合物在治疗中的用途,特别是用于治疗HM74A受体活化不足的疾病 具有式(II):其中R 1选自:氢和C 1-4烷基,其可以是该受体的活化或有利的活化,其可以是 任选被一个或多个选自CN和CF 3的基团取代,R 2选自:C 2-10未取代的烷基,C 被一个或多个选自氟和CN,C 5链烯基,未分支的C 4 - 4链烯基和C